

GLAXOSMITHKLINE PLC  
Form 6-K  
October 06, 2014

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending October 2014

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

In accordance with DTR 3.1.4R(1)(a) GlaxoSmithKline plc ('GSK') was advised on 6 October 2014, of changes in the interests of the following Persons Discharging Managerial Responsibility, following increases in their notional interests in Ordinary Shares, at a price of 1412.25 pence per Share, on the re-investment of dividends paid on Ordinary Shares held in the GlaxoSmithKline Deferred Investment Award Programme.

Director/PDMR	Ordinary Shares
---------------	-----------------

Mr R G Connor	374.938
---------------	---------

Mr S A Hussain	468.673
----------------	---------

Mr D S Redfern	374.938
----------------	---------

Ms C Thomas	374.938
-------------	---------

Dr P J T Vallance	468.673
-------------------	---------

Ms E Walmsley	859.185
---------------	---------

Mrs V A Whyte	104.950
---------------	---------

V A Whyte  
Company Secretary

6 October 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Date: October 06, 2014

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc